Insider Sales at Globus Medical: Profit-Taking or Warning Signal?
Published on 11/14/2025 at 10:23 | Redaktion boerse-global.de
While Globus Medical showcases exceptional financial performance with record-breaking results and elevated guidance, company directors are simultaneously executing multi-million dollar share sales. This divergence raises compelling questions about whether these transactions represent routine profit-taking or signal deeper concerns about the medical device manufacturer’s valuation.
The investment community maintains robust optimism for Globus Medical despite recent insider activity. Piper Sandler reinforced its “Overweight” stance while lifting its price target to $90. BofA Securities upgraded its rating from “Neutral” to “Buy” with a $91 target, and Truist Securities established the most bullish position with a “Buy” rating and $93 price objective. The consensus price target sits at $88.82, suggesting substantial upside potential from the current Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
